TY - JOUR
T1 - Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry
AU - Okuda, Ryo
AU - Ogura, Takashi
AU - Hisata, Shu
AU - Baba, Tomohisa
AU - Kondoh, Yasuhiro
AU - Suda, Takafumi
AU - Johkoh, Takeshi
AU - Iwasawa, Tae
AU - Tomioka, Hiromi
AU - Bando, Masashi
AU - Azuma, Arata
AU - Inoue, Yoshikazu
AU - Arai, Toru
AU - Nakamura, Yutaro
AU - Miyamoto, Atsushi
AU - Miyazaki, Yasunari
AU - Chiba, Hirofumi
AU - Ishii, Haruyuki
AU - Hamada, Naoki
AU - Terasaki, Yasuhiro
AU - Kuwahira, Ichiro
AU - Sato, Shinji
AU - Kato, Shingo
AU - Suzuki, Takuji
AU - Sakamoto, Susumu
AU - Nishioka, Yasuhiko
AU - Hattori, Noboru
AU - Hashimoto, Naozumi
AU - Morita, Satoshi
AU - Ichihara, Nao
AU - Miyata, Hiroaki
AU - Hagiwara, Koichi
AU - Nukiwa, Toshihiro
AU - Kobayashi, Kunihiko
N1 - Publisher Copyright:
© 2022 The Japanese Respiratory Society
PY - 2023/1
Y1 - 2023/1
N2 - Background: Numerous studies investigated patients with IPF; however, only a few examined patients with idiopathic interstitial pneumonias (IIPs). Methods: The Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry, which was initiated in December 2016, is a multicenter prospective observational study of patients newly diagnosed with IIPs from 86 facilities treating ILDs. The plan is to enroll more than 600 new patients during the 2-year enrolment period and to follow their progress for 3 years after the last case enrolment. If additional consent is obtained, the study will continue for another 2 years. Research questions mainly focus on identifying the frequency by IIP classification, patient background, and diagnostic methods during enrolment, survival, acute exacerbation rate, changes in high-resolution CT imaging, forced vital capacity, and interstitial pneumonia markers over time. Other research questions, including those regarding disease behavior in patients with progressive fibrosing-ILD and new biomarkers associated with genetic predispositions, will be investigated. Discussion: The JIPS Registry will provide a comprehensive description of the disease progression, prognosis, treatment status, new biomarkers, and validity of guidelines and central multidisciplinary decisions for IPF and similar diseases that can be differentiated from IPF among IIPs. Ethics and dissemination: Ethical approval was obtained from the institutional review board of Kanagawa Cardiovascular and Respiratory Center (KCRC-16-0005), and that of Jichi Medical University approved the biobank part (I18-005). Results will be published in peer-reviewed journals and will be presented at national and international conferences. Trial registration: ClinTrials.gov Registry (NCT03041623, first posted on February 3, 2017).
AB - Background: Numerous studies investigated patients with IPF; however, only a few examined patients with idiopathic interstitial pneumonias (IIPs). Methods: The Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry, which was initiated in December 2016, is a multicenter prospective observational study of patients newly diagnosed with IIPs from 86 facilities treating ILDs. The plan is to enroll more than 600 new patients during the 2-year enrolment period and to follow their progress for 3 years after the last case enrolment. If additional consent is obtained, the study will continue for another 2 years. Research questions mainly focus on identifying the frequency by IIP classification, patient background, and diagnostic methods during enrolment, survival, acute exacerbation rate, changes in high-resolution CT imaging, forced vital capacity, and interstitial pneumonia markers over time. Other research questions, including those regarding disease behavior in patients with progressive fibrosing-ILD and new biomarkers associated with genetic predispositions, will be investigated. Discussion: The JIPS Registry will provide a comprehensive description of the disease progression, prognosis, treatment status, new biomarkers, and validity of guidelines and central multidisciplinary decisions for IPF and similar diseases that can be differentiated from IPF among IIPs. Ethics and dissemination: Ethical approval was obtained from the institutional review board of Kanagawa Cardiovascular and Respiratory Center (KCRC-16-0005), and that of Jichi Medical University approved the biobank part (I18-005). Results will be published in peer-reviewed journals and will be presented at national and international conferences. Trial registration: ClinTrials.gov Registry (NCT03041623, first posted on February 3, 2017).
KW - Epidemiology
KW - Idiopathic pulmonary fibrosis
KW - Progressive fibrosing interstitial lung disease
KW - Protocol
UR - http://www.scopus.com/inward/record.url?scp=85141941396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141941396&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2022.08.009
DO - 10.1016/j.resinv.2022.08.009
M3 - Article
C2 - 36580379
AN - SCOPUS:85141941396
SN - 2212-5345
VL - 61
SP - 95
EP - 102
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 1
ER -